5 / 10
Page 15
Notes:
J Pharmacol Ther Res 2017 Volume 1 Issue 2
allied
academies
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
P
atientrecruitmentandretentionarekeyfactors,andgenerally
the most challenging, in meeting the objectives and success
of clinical trials. Clinical trial costs, complexity and development
timelines have continued to increase over the past several years
as well as the burden to participating patients and caregivers.
We are approaching a critical juncture where traditional trial
designs can no longer be justified or sustained. More patient-
centric trial models and novel trial designs incorporating mobile
technologies are available to make studies more patient-
friendly as well as more cost efficient. A patient-centric service
model has evolved over the past two decades allowing study
visits to be conducted at the patient’s home where it is more
convenient and comfortable than at the investigator site. By
conducting selected protocol visits at home, the workplace or
other alternate location, ambulant healthcare providers offer
a way for patients to participate in trials regardless of typical
barriers of studyduration, visit frequency, disease state, distance
to site, site office hours, or family, school or work obligations.
By making trials more convenient for patients, this service
model has demonstrated that more patients are willing and
able to participate and remain in studies. Virtual study (central-
site) designs have been introduced to also address real world
challenges to gain access to hard to reach patients residing in
rural areas and those who may have mobility issues and to
utilize available technologies to remotely consent and monitor
patients. There remains the need for local clinical support
to obtain safety labs or train patients on utilizing the mobile
devices. The use of ambulant healthcare providers to conduct
at-home study visits can result in significantly more cost-
effective, efficient and patient-friendly clinical trial programs
conducted globally than traditional studies. This session will
explore the use of an innovative, patient-centric approach to
conducting selected study visits via an ambulant healthcare
network to reduce patient burden and other barriers to study
participation; Show, how conducting selected protocol visits
at the patient’s home or alternate location rather than at the
investigator site can make study participation more convenient
and comfortable for patients resulting in faster recruitment and
better compliance and retention; Present case studies using
ambulant care services and demonstrate win-win benefits for
all stakeholders.
Speaker Biography
Gail Adinamis is Founder and CEO of GlobalCare Clinical Trials, LLC, a global niche
patient-centric service organization that takes study visits to the patient’s home or
alternate setting via a global network of ambulant healthcare providers in over 60
countries. She has over 35 years of comprehensive global clinical trials experience
including over 12 years of global trials management at Abbott Laboratories and Astellas.
She has founded the in-home business model for study visits in 1992 and established
and headed clinical trials divisions for three national home infusion companies and was
a Founder, President and CEO of the first independent ambulant care service company
for clinical trials. She is a Member of the Women Presidents’ Organization, National
Association of Professional Women, and DIA and has been an Invited Speaker at several
industry conferences and recipient of numerous awards/recognitions including twice
being among INC 5000’s fastest growing private companies, and Game Changer and
CEO of the Year.
e:
gadinamis@globalcarect.comGail Adinamis
GlobalCare Clinical Trials, USA
Innovative patient-centric service model helps speed patient recruitment and increase
retention in virtual and traditional study designs